Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer

Bhavana Konda, Eric J. Sherman, Erminia Massarelli, Jorge J. Nieva, Jameel Muzaffar, Peter R. Schofield, Mabel Ryder, Alan L. Ho, Mark Agulnik, Lai Wei, Demond Handley, Catherine Moses, Rajani Jacob, John Wright, Howard Streicher, William E. Carson, Manisha H. ShahThe Journal of Clinical Endocrinology & Metabolism 2024 · DOI

Abstract

NCT03914300.
BibTeX
@article{konda2024cabozantinib,
  author = {Bhavana Konda and Eric J. Sherman and Erminia Massarelli and Jorge J. Nieva and Jameel Muzaffar and Peter R. Schofield and Mabel Ryder and Alan L. Ho and Mark Agulnik and Lai Wei and Demond Handley and Catherine Moses and Rajani Jacob and John Wright and Howard Streicher and William E. Carson and Manisha H. Shah},
  title = {{Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer}},
  journal = {The Journal of Clinical Endocrinology \& Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae512},
}

Loading related content...

Figure